The congenital heart defect devices market size has grown strongly in recent years. It will grow from $3.11 billion in 2025 to $3.34 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to rising incidence of congenital heart defects, advancements in pediatric cardiac surgery, increasing survival rates of congenital heart patients, expansion of specialized cardiac care centers, growing awareness of early congenital defect diagnosis.
The congenital heart defect devices market size is expected to see strong growth in the next few years. It will grow to $4.45 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing focus on early diagnosis and intervention, rising demand for minimally invasive pediatric cardiac treatments, expanding access to advanced cardiac care in emerging markets, growing population of adults with congenital heart disease, continuous innovation in implantable cardiac devices. Major trends in the forecast period include rising adoption of minimally invasive congenital heart procedures, increasing use of transcatheter and implantable cardiac devices, growing focus on early-life and pediatric cardiac interventions, expansion of device-based therapies for complex heart defects, increasing demand for long-term cardiac monitoring and support devices.
The growth of the congenital heart defect device market is anticipated to be driven by the rising number of minimally invasive procedures. These procedures involve performing surgeries through small incisions or natural body openings, using specialized tools and techniques to minimize trauma and improve recovery. Factors contributing to the increase in minimally invasive procedures include technological advancements, patient preference for less invasive treatments, enhanced surgical techniques, and the advantages of reduced recovery times and complications. Congenital heart defect devices play a crucial role in these procedures by enabling the diagnosis, treatment, and management of heart abnormalities through smaller incisions or catheter-based approaches. For example, in June 2024, according to the American Society of Plastic Surgeons, a US-based organization, plastic surgeries in 2023 increased by 5%, while minimally invasive procedures grew by 7% compared to the previous year. This rise in minimally invasive procedures is consequently boosting the congenital heart defect device market.
Major players in the congenital heart defect (CHD) devices market are increasingly forming strategic partnerships to develop innovative solutions. These partnerships help companies in the CHD devices sector by combining resources and expertise, enhancing research and development efforts, expanding market reach, and accelerating the commercialization process. Such collaborations foster innovation and contribute to industry growth. For example, in May 2024, SMT (Sahajanand Medical Technologies Pvt Ltd), an India-based manufacturing company, entered into a partnership with HeartX, an India-based MedTech firm, to improve patient care in the cardiovascular sector. Through this collaboration, Sahajanand Medical Technologies (SMT) strengthens its presence in the CHD market by incorporating HeartX's cutting-edge solutions, such as the JOVE VB Stent. This alliance enables SMT to provide advanced CHD devices that improve treatment effectiveness, simplify procedures, and enhance patient outcomes.
In June 2023, Translumina Therapeutics LLP, an India-based cardiovascular device manufacturer, acquired Wellinq Group Company for an undisclosed sum. This acquisition aims to broaden Translumina’s cardiovascular and endovascular solutions portfolio and strengthen its market presence in the Netherlands by integrating Blue Medical Devices’ innovative technologies and expertise. Wellinq Group Company, based in the Netherlands, specializes in developing and manufacturing products for treating congenital heart defects.
Major companies operating in the congenital heart defect devices market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, W L Gore & Associates Inc, Lepu Medical Technology Beijing Co Ltd, MicroPort Scientific Corporation, Berlin Heart GmbH, Syncardia Systems LLC, Occlutech Holding AG, Sahajanand Medical Technologies Pvt Ltd, Xeltis AG, Procyrion Inc, Heartstitch Inc, Cardia Inc, OSYPKA Medical GmbH, On-X Life Technologies Inc, Ventracor Limited, HemoFlow Technologies, NuPulseCV Inc.
North America was the largest region in the congenital heart defect devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congenital heart defect devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the congenital heart defect devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the congenital heart defect devices market by increasing costs for imported medical-grade materials, electronic components, and precision-engineered parts used in pacemakers, catheters, and implantable cardiac devices. These cost pressures have particularly affected advanced implantable and transcatheter device segments, with north america and europe experiencing higher exposure due to complex global supply chains. Increased tariffs have raised procurement costs for hospitals and specialty clinics. However, tariffs have also encouraged localized manufacturing, supplier diversification, and regional production expansion, strengthening long-term supply chain resilience.
The congenital heart defect devices market research report is one of a series of new reports that provides congenital heart defect devices market statistics, including congenital heart defect devices industry global market size, regional shares, competitors with a congenital heart defect devices market share, detailed congenital heart defect devices market segments, market trends and opportunities, and any further data you may need to thrive in the congenital heart defect devices industry. This congenital heart defect devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Congenital heart defect devices are specialized medical instruments and implants designed to address and manage heart abnormalities present from birth. These devices are used to diagnose, treat, and support the heart's function in individuals with congenital heart defects, aiming to restore normal blood flow and enhance cardiac performance.
The primary types of congenital heart defect devices include catheters, pacemakers (single-chamber, dual-chamber, biventricular, and leadless), implantable cardioverter defibrillators, biventricular devices, and implanted cardiac loop recorders. Catheters are slender, flexible tubes inserted into the body for various functions such as diagnostic, therapeutic, or monitoring purposes. These devices are used for different types of congenital defects, including ventricular septal defect, atrioventricular septal defect, tricuspid atresia, truncus arteriosus, and others. They are employed by hospitals, specialty clinics, academic and research institutions, and other healthcare settings.
The congenital heart defect devices market consists of sales of septal occluders, heart valves, patent ductus arteriosus (PDA) devices, and bioprosthetic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The congenital heart defect devices market size is expected to see strong growth in the next few years. It will grow to $4.45 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing focus on early diagnosis and intervention, rising demand for minimally invasive pediatric cardiac treatments, expanding access to advanced cardiac care in emerging markets, growing population of adults with congenital heart disease, continuous innovation in implantable cardiac devices. Major trends in the forecast period include rising adoption of minimally invasive congenital heart procedures, increasing use of transcatheter and implantable cardiac devices, growing focus on early-life and pediatric cardiac interventions, expansion of device-based therapies for complex heart defects, increasing demand for long-term cardiac monitoring and support devices.
The growth of the congenital heart defect device market is anticipated to be driven by the rising number of minimally invasive procedures. These procedures involve performing surgeries through small incisions or natural body openings, using specialized tools and techniques to minimize trauma and improve recovery. Factors contributing to the increase in minimally invasive procedures include technological advancements, patient preference for less invasive treatments, enhanced surgical techniques, and the advantages of reduced recovery times and complications. Congenital heart defect devices play a crucial role in these procedures by enabling the diagnosis, treatment, and management of heart abnormalities through smaller incisions or catheter-based approaches. For example, in June 2024, according to the American Society of Plastic Surgeons, a US-based organization, plastic surgeries in 2023 increased by 5%, while minimally invasive procedures grew by 7% compared to the previous year. This rise in minimally invasive procedures is consequently boosting the congenital heart defect device market.
Major players in the congenital heart defect (CHD) devices market are increasingly forming strategic partnerships to develop innovative solutions. These partnerships help companies in the CHD devices sector by combining resources and expertise, enhancing research and development efforts, expanding market reach, and accelerating the commercialization process. Such collaborations foster innovation and contribute to industry growth. For example, in May 2024, SMT (Sahajanand Medical Technologies Pvt Ltd), an India-based manufacturing company, entered into a partnership with HeartX, an India-based MedTech firm, to improve patient care in the cardiovascular sector. Through this collaboration, Sahajanand Medical Technologies (SMT) strengthens its presence in the CHD market by incorporating HeartX's cutting-edge solutions, such as the JOVE VB Stent. This alliance enables SMT to provide advanced CHD devices that improve treatment effectiveness, simplify procedures, and enhance patient outcomes.
In June 2023, Translumina Therapeutics LLP, an India-based cardiovascular device manufacturer, acquired Wellinq Group Company for an undisclosed sum. This acquisition aims to broaden Translumina’s cardiovascular and endovascular solutions portfolio and strengthen its market presence in the Netherlands by integrating Blue Medical Devices’ innovative technologies and expertise. Wellinq Group Company, based in the Netherlands, specializes in developing and manufacturing products for treating congenital heart defects.
Major companies operating in the congenital heart defect devices market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, W L Gore & Associates Inc, Lepu Medical Technology Beijing Co Ltd, MicroPort Scientific Corporation, Berlin Heart GmbH, Syncardia Systems LLC, Occlutech Holding AG, Sahajanand Medical Technologies Pvt Ltd, Xeltis AG, Procyrion Inc, Heartstitch Inc, Cardia Inc, OSYPKA Medical GmbH, On-X Life Technologies Inc, Ventracor Limited, HemoFlow Technologies, NuPulseCV Inc.
North America was the largest region in the congenital heart defect devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congenital heart defect devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the congenital heart defect devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the congenital heart defect devices market by increasing costs for imported medical-grade materials, electronic components, and precision-engineered parts used in pacemakers, catheters, and implantable cardiac devices. These cost pressures have particularly affected advanced implantable and transcatheter device segments, with north america and europe experiencing higher exposure due to complex global supply chains. Increased tariffs have raised procurement costs for hospitals and specialty clinics. However, tariffs have also encouraged localized manufacturing, supplier diversification, and regional production expansion, strengthening long-term supply chain resilience.
The congenital heart defect devices market research report is one of a series of new reports that provides congenital heart defect devices market statistics, including congenital heart defect devices industry global market size, regional shares, competitors with a congenital heart defect devices market share, detailed congenital heart defect devices market segments, market trends and opportunities, and any further data you may need to thrive in the congenital heart defect devices industry. This congenital heart defect devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Congenital heart defect devices are specialized medical instruments and implants designed to address and manage heart abnormalities present from birth. These devices are used to diagnose, treat, and support the heart's function in individuals with congenital heart defects, aiming to restore normal blood flow and enhance cardiac performance.
The primary types of congenital heart defect devices include catheters, pacemakers (single-chamber, dual-chamber, biventricular, and leadless), implantable cardioverter defibrillators, biventricular devices, and implanted cardiac loop recorders. Catheters are slender, flexible tubes inserted into the body for various functions such as diagnostic, therapeutic, or monitoring purposes. These devices are used for different types of congenital defects, including ventricular septal defect, atrioventricular septal defect, tricuspid atresia, truncus arteriosus, and others. They are employed by hospitals, specialty clinics, academic and research institutions, and other healthcare settings.
The congenital heart defect devices market consists of sales of septal occluders, heart valves, patent ductus arteriosus (PDA) devices, and bioprosthetic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Congenital Heart Defect Devices Market Characteristics
3. Congenital Heart Defect Devices Market Supply Chain Analysis
4. Global Congenital Heart Defect Devices Market Trends and Strategies
5. Congenital Heart Defect Devices Market Analysis of End Use Industries
7. Global Congenital Heart Defect Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Congenital Heart Defect Devices Total Addressable Market (TAM) Analysis for the Market
9. Congenital Heart Defect Devices Market Segmentation
10. Congenital Heart Defect Devices Market Regional and Country Analysis
11. Asia-Pacific Congenital Heart Defect Devices Market
12. China Congenital Heart Defect Devices Market
13. India Congenital Heart Defect Devices Market
14. Japan Congenital Heart Defect Devices Market
15. Australia Congenital Heart Defect Devices Market
16. Indonesia Congenital Heart Defect Devices Market
17. South Korea Congenital Heart Defect Devices Market
18. Taiwan Congenital Heart Defect Devices Market
19. South East Asia Congenital Heart Defect Devices Market
20. Western Europe Congenital Heart Defect Devices Market
21. UK Congenital Heart Defect Devices Market
22. Germany Congenital Heart Defect Devices Market
23. France Congenital Heart Defect Devices Market
24. Italy Congenital Heart Defect Devices Market
25. Spain Congenital Heart Defect Devices Market
26. Eastern Europe Congenital Heart Defect Devices Market
27. Russia Congenital Heart Defect Devices Market
28. North America Congenital Heart Defect Devices Market
29. USA Congenital Heart Defect Devices Market
30. Canada Congenital Heart Defect Devices Market
31. South America Congenital Heart Defect Devices Market
32. Brazil Congenital Heart Defect Devices Market
33. Middle East Congenital Heart Defect Devices Market
34. Africa Congenital Heart Defect Devices Market
36. Congenital Heart Defect Devices Market Competitive Landscape and Company Profiles
37. Congenital Heart Defect Devices Market Other Major and Innovative Companies
40. Congenital Heart Defect Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Congenital Heart Defect Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses congenital heart defect devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for congenital heart defect devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The congenital heart defect devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Device Type: Catheters; Pacemakers; Single-Chamber Pacemakers; Dual-Chamber Pacemakers; Biventricular Pacemakers; Leadless Pacemakers; Implantable Cardioverter Defibrillators; Biventricular Devices; Implanted Cardiac Loop Recorders; Other Device Types2) By Defect Type: Atrial Septal Defect; Ventricular Septal Defect; Atrioventricular Septal Defect; Tricuspid Atresia; Truncus Arteriosus; Other Defect Types
3) By End user: Hospitals; Specialty Clinics; Academic And Research Institute; Other End Users
Subsegments:
1) By Catheters: Balloon Catheters; Diagnostic Catheters; Guiding Catheters2) By Pacemakers: Single-Chamber Pacemakers; Dual-Chamber Pacemakers; Biventricular Pacemakers; Leadless Pacemakers
3) By Implantable Cardioverter Defibrillators: Single-Chamber Icds; Dual-Chamber Icds; Subcutaneous Icds
4) By Biventricular Devices: Crt-P (Cardiac Resynchronization Therapy Pacemakers); Crt-D (Cardiac Resynchronization Therapy Defibrillators)
5) By Implanted Cardiac Loop Recorders: Traditional Implantable Loop Recorders; Subcutaneous Implantable Loop Recorders
6) By Other Device Types: Transcatheter Heart Valves; Ventricular Assist Devices (VADS)
Companies Mentioned: Johnson & Johnson; Abbott Laboratories; Medtronic plc; Boston Scientific Corporation; W L Gore & Associates Inc; Lepu Medical Technology Beijing Co Ltd; MicroPort Scientific Corporation; Berlin Heart GmbH; Syncardia Systems LLC; Occlutech Holding AG; Sahajanand Medical Technologies Pvt Ltd; Xeltis AG; Procyrion Inc; Heartstitch Inc; Cardia Inc; OSYPKA Medical GmbH; On-X Life Technologies Inc; Ventracor Limited; HemoFlow Technologies; NuPulseCV Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Congenital Heart Defect Devices market report include:- Johnson & Johnson
- Abbott Laboratories
- Medtronic plc
- Boston Scientific Corporation
- W L Gore & Associates Inc
- Lepu Medical Technology Beijing Co Ltd
- MicroPort Scientific Corporation
- Berlin Heart GmbH
- Syncardia Systems LLC
- Occlutech Holding AG
- Sahajanand Medical Technologies Pvt Ltd
- Xeltis AG
- Procyrion Inc
- Heartstitch Inc
- Cardia Inc
- OSYPKA Medical GmbH
- On-X Life Technologies Inc
- Ventracor Limited
- HemoFlow Technologies
- NuPulseCV Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.34 Billion |
| Forecasted Market Value ( USD | $ 4.45 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
